Polaris Genomics

Executive Summary

Polaris Genomics is a privately held biotechnology company pioneering objective, biology-based diagnostic tools for mental and brain health. By leveraging a proprietary genomic and machine learning platform, the company analyzes biomarker signatures from routine blood samples to enable more accurate assessment, diagnosis, and personalized treatment of neuropsychiatric conditions such as depression, anxiety, and PTSD. Founded in 2015 and headquartered in Rockville, Maryland, Polaris addresses a critical gap in psychiatry: the lack of objective, quantifiable measures to guide clinical decisions. Current diagnostic methods rely on subjective self-reporting and clinical observation, leading to misdiagnosis and trial-and-error treatment. Polaris's liquid biopsy approach has the potential to transform mental healthcare by providing clinicians with reproducible biomarkers, improving patient outcomes and reducing healthcare costs. As an early-stage company without disclosed funding or commercial products, Polaris operates in a high-risk, high-reward space, but its focus on validated biomarkers and scalable technology positions it to capture significant value as the demand for precision psychiatry grows.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation data for depression or PTSD biomarker panel60% success
• Q2 2027FDA Breakthrough Device designation or submission for 510(k) clearance30% success
• Q3 2026Series A funding round or strategic partnership with major pharma/mental health provider40% success